{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  acalabrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"aciclovir\" outputclass=\"int-drug\">aciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  aciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"adefovir\" outputclass=\"int-drug\">adefovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  adefovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adefovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"alendronate\" outputclass=\"int-drug\">alendronate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   is predicted to   increase   the risk of gastrointestinal irritation when given with   alendronate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  alprostadil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"amikacin\" outputclass=\"int-drug\">amikacin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  amikacin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amikacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985401_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"amphotericin B\" outputclass=\"int-drug\">amphotericin B</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  amphotericin B  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin B</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  anagrelide  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  aspirin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  axitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"bacitracin\" outputclass=\"int-drug\">bacitracin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  bacitracin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacitracin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">beclometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   beclometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">bemiparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  bemiparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985412_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">Bemiparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bemiparin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985413_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   bendroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">betamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   betamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   bevacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  bosutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"budesonide\" outputclass=\"int-drug\">budesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   budesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   cabozantinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cangrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"caplacizumab\" outputclass=\"int-drug\">caplacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   caplacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Caplacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"capreomycin\" outputclass=\"int-drug\">capreomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  capreomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capreomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  carboplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefaclor\" outputclass=\"int-drug\">cefaclor</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefaclor  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefaclor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefadroxil\" outputclass=\"int-drug\">cefadroxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefadroxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefadroxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefalexin\" outputclass=\"int-drug\">cefalexin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefalexin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefalexin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefazolin\" outputclass=\"int-drug\">cefazolin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefazolin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefazolin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefepime\" outputclass=\"int-drug\">cefepime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefepime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefepime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefixime\" outputclass=\"int-drug\">cefixime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefixime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefixime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefotaxime\" outputclass=\"int-drug\">cefotaxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefotaxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefotaxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefoxitin\" outputclass=\"int-drug\">cefoxitin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefoxitin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefoxitin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefradine\" outputclass=\"int-drug\">cefradine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefradine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ceftaroline\" outputclass=\"int-drug\">ceftaroline</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ceftaroline  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftaroline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ceftazidime\" outputclass=\"int-drug\">ceftazidime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ceftazidime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftazidime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">ceftobiprole</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ceftobiprole  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ceftolozane\" outputclass=\"int-drug\">ceftolozane</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ceftolozane  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftolozane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ceftriaxone\" outputclass=\"int-drug\">ceftriaxone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ceftriaxone  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftriaxone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cefuroxime\" outputclass=\"int-drug\">cefuroxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cefuroxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefuroxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985443_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   chlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985444_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   chlortalidone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"ciclesonide\" outputclass=\"int-drug\">ciclesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   ciclesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ciclosporin  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985446_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cidofovir\" outputclass=\"int-drug\">cidofovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cidofovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cidofovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cilostazol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ciprofloxacin\" outputclass=\"int-drug\">ciprofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   potentially   increases   the risk of seizures when given with   ciprofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  cisplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  citalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985451_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  citalopram  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"clodronate\" outputclass=\"int-drug\">clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   is predicted to   increase   the risk of renal impairment when given with   clodronate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  clopidogrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cobimetinib\" outputclass=\"int-drug\">cobimetinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   cobimetinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobimetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"colistimethate\" outputclass=\"int-drug\">Colistimethate</ph> <ph outputclass=\"int-substanceQualifier\">(particularly intravenous)</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of nephrotoxicity when given with</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Colistimethate   (particularly intravenous)   potentially   increases   the risk of nephrotoxicity when given with   meloxicam .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colistimethate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985458_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dalteparin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  dapoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985460_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  dapoxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"daptomycin\" outputclass=\"int-drug\">daptomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of renal impairment when given with   daptomycin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  dasatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">deferasirox</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   is predicted to   increase   the risk of gastrointestinal bleeding when given with   deferasirox .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"delafloxacin\" outputclass=\"int-drug\">delafloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   potentially   increases   the risk of seizures when given with   delafloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delafloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">dexamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   dexamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  dipyridamole  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985473_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  duloxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"eicosapentaenoic acid\" outputclass=\"int-drug\">eicosapentaenoic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  eicosapentaenoic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eicosapentaenoic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985477_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Enoxaparin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985478_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  epoprostenol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">Eptifibatide</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eptifibatide   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">Erlotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erlotinib   is predicted to   increase   the risk of gastrointestinal perforation when given with   meloxicam .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  escitalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985486_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  escitalopram  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">fludrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   fludrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  fluoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985488_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  fluoxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fluticasone\" outputclass=\"int-drug\">fluticasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   fluticasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluticasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  fluvoxamine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985490_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  fluvoxamine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"foscarnet\" outputclass=\"int-drug\">foscarnet</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  foscarnet  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Foscarnet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"gentamicin\" outputclass=\"int-drug\">gentamicin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  gentamicin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gentamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"heparin\" outputclass=\"int-drug\">heparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  heparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985497_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin\" outputclass=\"int-drug\">Heparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Heparin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985498_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   hydrochlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">hydrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   hydrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985500_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   hydroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"ibandronate\" outputclass=\"int-drug\">ibandronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   is predicted to   increase   the risk of gastrointestinal irritation when given with   ibandronate .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ibrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ifosfamide  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  iloprost  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  imatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985508_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   indapamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  inotersen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985509_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   inotersen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  lenvatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"levofloxacin\" outputclass=\"int-drug\">levofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   potentially   increases   the risk of seizures when given with   levofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  methotrexate  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985516_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of toxicity when given with</ph> <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   is predicted to   increase   the risk of toxicity when given with   methotrexate .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">methylprednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   methylprednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985518_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   metolazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   (high-dose)   is predicted to   decrease   the efficacy of   mifamurtide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"mometasone\" outputclass=\"int-drug\">mometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   mometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   potentially   increases   the risk of seizures when given with   moxifloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"neomycin\" outputclass=\"int-drug\">neomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  neomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">Nicorandil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicorandil   is predicted to   increase   the risk of gastrointestinal perforation when given with   meloxicam .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  nintedanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ofloxacin\" outputclass=\"int-drug\">ofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   potentially   increases   the risk of seizures when given with   ofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">omega-3-acid ethyl esters</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  omega-3-acid ethyl esters  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  oxaliplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  paroxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985531_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  paroxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  pazopanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  pemetrexed  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985533_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   is predicted to   increase   the exposure to   pemetrexed .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"penicillamine\" outputclass=\"int-drug\">penicillamine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  penicillamine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Penicillamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  pentamidine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"polymyxin b\" outputclass=\"int-drug\">polymyxin b</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  polymyxin b  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Polymyxin b</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ponatinib\" outputclass=\"int-drug\">ponatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ponatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  prasugrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">prednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   prednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  regorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  sertraline  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985550_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  sertraline  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  sorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985553_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"streptomycin\" outputclass=\"int-drug\">streptomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  streptomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  streptozocin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  sunitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  tacrolimus  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985558_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  tenofovir disoproxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  ticagrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985563_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">Tirofiban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tirofiban   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"tobramycin\" outputclass=\"int-drug\">tobramycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  tobramycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tobramycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   trametinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   trastuzumab emtansine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  treprostinil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">triamcinolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the risk of gastrointestinal bleeding when given with   triamcinolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985573_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985574_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  meloxicam  and  trimethoprim  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985574_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  meloxicam  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985576",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985576_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985577",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985577_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"valaciclovir\" outputclass=\"int-drug\">valaciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  valaciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valaciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985578",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985578_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  valganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985579",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985579_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985580",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985580_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"vancomycin\" outputclass=\"int-drug\">vancomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  vancomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vancomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985581",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985581_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  venlafaxine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"volanesorsen\" outputclass=\"int-drug\">volanesorsen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid depending on platelet countconsult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   volanesorsen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises avoid depending on platelet countconsult product literature .    \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Volanesorsen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  vortioxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985585_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Meloxicam   increases   the risk of acute renal failure when given with   xipamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  zidovudine  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985586_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">Zidovudine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of haematological toxicity when given with</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zidovudine   increases   the risk of haematological toxicity when given with   meloxicam .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2#bnf_i1643857985587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"meloxicam\" outputclass=\"int-heading-drug\">meloxicam</ph> and <ph otherprops=\"zoledronate\" outputclass=\"int-drug\">zoledronate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  meloxicam  and  zoledronate  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zoledronate</title>"
					}
				}
			],
			"hasSearchLabel": " Meloxicam  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/meloxicam-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Meloxicam </title>"
			},
			"rdfs:label": "meloxicam"
		}
	]
}